Mediolanum International Funds Ltd Purchases 46,183 Shares of Abbott Laboratories $ABT

Key Points

• Mediolanum International Funds Ltd increased its Abbott Laboratories stake by 83.7% in Q1, buying 46,183 additional shares and bringing its total holdings to 101,359 shares worth about $10.3 million.
• Abbott beat Q2 earnings expectations with EPS of $1.31 and reported 13% revenue growth year over year, then raised its full-year 2026 EPS guidance to $5.45-$5.60.
• The stock has drawn mixed but mostly constructive sentiment from Wall Street, with several analysts raising targets after the results and a consensus rating of Moderate Buy; Abbott also pays a quarterly dividend of $0.63 per share.

Mediolanum International Funds Ltd grew its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 83.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,359 shares of the healthcare product maker's stock after purchasing an additional 46,183 shares during the period. Mediolanum International Funds Ltd's holdings in Abbott Laboratories were worth $10,326,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.0%

ABT stock opened at $100.71 on Monday. The company has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company's 50 day moving average price is $89.89 and its two-hundred day moving average price is $102.01.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories's payout ratio is currently 81.55%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the firm's stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company's stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company's stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday. Daiwa Securities Group downgraded shares of Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Barclays cut their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research report on Monday, April 20th. Argus reduced their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Finally, Benchmark lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.61.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.